Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Medtronic
Boehringer Ingelheim
Farmers Insurance
Cantor Fitzgerald
Chubb
Accenture
Novartis
McKesson
Deloitte

Generated: August 17, 2017

DrugPatentWatch Database Preview

ARICEPT ODT Drug Profile

« Back to Dashboard

Which patents cover Aricept Odt, and when can generic versions of Aricept Odt launch?

Aricept Odt is a drug marketed by Eisai Inc and is included in one NDA.

The generic ingredient in ARICEPT ODT is donepezil hydrochloride. There are thirty-one drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

Summary for Tradename: ARICEPT ODT

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list63
Clinical Trials: see list128
Patent Applications: see list2,811
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ARICEPT ODT at DailyMed

Pharmacology for Tradename: ARICEPT ODT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004ABRXYesNo► Subscribe► Subscribe► Subscribe
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-002Oct 18, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ARICEPT ODT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004► Subscribe► Subscribe
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-002Oct 18, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ARICEPT ODT

Drugname Dosage Strength RLD Submissiondate
donepezil hydrochlorideOrally Disintegrating Tablets5 mg and 10 mgAricept ODT6/30/2010
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Novartis
Merck
Daiichi Sankyo
Healthtrust
Queensland Health
Express Scripts
Colorcon
Federal Trade Commission
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot